FGFR3 and Miyoshi myopathy: The t(4;14)(p16.3;q32) occurs in 15-20% of myeloma patients and leads to the overexpression of FGFR3 gene and, in turn, the constitutive activation of several signaling pathways in 80% of t(4;14)+ MM patients.